Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

3T MRI to Predict TACE Response of HCC

23. februar 2014 oppdatert av: National Taiwan University Hospital

Combination of Dynamic Contrast-enhanced and Diffusion-weighted Imaging and Magnetic Resonance Spectroscopy in 3T MRI to Early Predict Treatment Efficacy in Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma

This study is a prospective clinical study using DCE-MRI, DWI and MRS in 3T scanner to evaluate tumors in patients with unresectable HCC after TACE. A total of 100 subjects will be recruited. MRI will be performed before TACE (day 0), day 14, and day 28 to assess the tumor responses. After day 28, all subjects will receive standard clinical care and be follow-up for 1 year. The imaging parameters will be compared among each MRI and correlate with patients' outcome. The investigators hypothesis that it might be helpful to combine DCE-MRI, DWI, and MRS for assessment of tumor response after TACE and predict patients' prognosis.

Studieoversikt

Status

Ukjent

Forhold

Karsinom, hepatocellulært

Detaljert beskrivelse

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a non-invasive quantitative technique for assessing micro-vascular structure by tracking the pharmacokinetics of injected low-molecular weight contrast agents as they pass through the tumor vasculature. This modality is being increasingly used in many oncological studies to characterize tumor angiogenesis and invasiveness, and monitor the treatment response.

Diffusion-weighted imaging (DWI) enables qualitative and quantitative assessment of tissue diffusivity (apparent diffusion coefficient, ADC) without the use of gadolinium chelates. DWI has been suggested to be useful in monitoring the response of HCC after TACE because of earlier assessment of tumor necrosis with increasing ADC values.

MR spectroscopy facilitates the study of cellular metabolism and in vivo detection of abnormalities. A few studies of in vivo MR spectroscopy reported an increase in choline levels within tumors such as HCC and a reduction in the lipid-to-choline ratio after conventional TACE was performed for HCC.

Studietype

Observasjonsmessig

Registrering (Forventet)

100

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Taiwan
- - Taipei, Taiwan, 100
    - Rekruttering
    - National Taiwan Uinversity Hospital
    - Ta kontakt med:
      
      Bang-Bin Chen, MD
      
      E-post: bangbin@gmail.com
    - Hovedetterforsker:
      
      Bang-Bin Chen, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

20 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Hospital patients, admitted for TACE treatment of HCC

Beskrivelse

Inclusion Criteria:

Prior Informed Consent Form
Patients who had undergone surgery for the treatment of HCC are allowed.
At least one measurable tumor, according to RECIST version 1.1.
Age more than 20 years.
ECOG performance status 0 or 1.
Life expectancy more than 3 months.
Child-Pugh class A.
Unresectable, multinodular tumors
Confirmed Diagnosis of HCC
At least one uni-dimensional lesion measurable according to the Modified RECIST criteria by MRI
Adequate bone marrow, liver and renal function

Exclusion Criteria:

History of TACE
Diffuse infiltrative HCC or presence of main portal vein invasion or extrahepatic metastasis
Any contraindications for hepatic embolization procedures:, including hepatofugal blood flow, large intrahepatic or porto-systemic shunt, impaired clotting test, renal failure requiring hemo-or peritoneal dialysis
Any contraindication for MRI, including known contrast allergy, electronically operated implants or devices, and claustrophobia.
Other acute or chronic medical, psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation and is inappropriate for this study by the judgment of the investigator
Known history of HIV infection
Concurrent primary extrahepatic cancer
Pregnant or breast-feeding subjects

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Antall grupper / kohorter

Kohorter og intervensjoner

Gruppe / Kohort
TACE patients, for HCC unresectable HCC patients

Hva måler studien?

Primære resultatmål

Resultatmål	Tiltaksbeskrivelse	Tidsramme
tumor response Tidsramme: change of tumor size from baseline to at 6 months	change of tumor size from baseline to at 6 months	change of tumor size from baseline to at 6 months

Sekundære resultatmål

Resultatmål	Tiltaksbeskrivelse	Tidsramme
change of baseline MRI parameters Tidsramme: change of MRI parameters from baseline to at 6 months	comparsion of MRI parameters from baseline to 6 months	change of MRI parameters from baseline to at 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

National Taiwan University Hospital

Etterforskere

Hovedetterforsker: Bang-Bin Chen, MD, National Taiwan Uinversity Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. august 2011

Primær fullføring (Forventet)

1. desember 2014

Studiet fullført (Forventet)